drugset / Trial / NCT05947435

Tranexamic Acid in Percutaneous Nephrolithotomy

NCT05947435 ↗

RandomizedParallel-groupDouble-blindPrevention

Summary

Tranexamic acid, once a randomly used antifibrinolytic agent, has been in standard protocols for many specific surgeries. Studies are still needed to standardize the dose and route of tranexamic acid administration, examine its possible contributions in urological surgery, and establish a protocol for its use. To contribute to this goal, the study was designed as a prospective, randomized, double-blind study on 75 patients with one control and 2 study groups (n=25) who underwent percutaneous nephrolithotomy. Group Tranexamic acid received 10 mg/kg intravenous tranexamic acid preoperatively. And Group Irrigation received the same amount in the initial irrigation fluid. Primarily,the total amount of blood transfusion and the changes in haemoglobin and haematocrit values during two postoperative days were observed. Distinctively, continuous intraoperative haemoglobin saturation was monitored. Secondarily, surgical visual clarity with a standard visual score was questioned to reveal its contribution to surgical practicality, operative time, and residual fragment quantity.

Timeline

Start
2022-01-01
Primary completion
2023-05-01
Completion
2023-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 10 mg/kg Intravenous

Indications